
Inflammation and cell proliferation signatures: Implications for response to immune checkpoint inhibition therapies
by Christina Black | Jun 19, 2020
View the published publication
Tumor inflammatory signature as a biomarker of response to immunotherapy in lung cancer
by Christina Black | Jun 19, 2020
View the published articleFollow Us on Twitter
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
https://tinyurl.com/muxryphz